FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * Silva Francisco 2. Issuer Name and Ticker or Trading Symbol BioRestorative Therapies, Inc. [ BRTX ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
VP of Research and Development
(Last)          (First)          (Middle)
40 MARCUS DRIVE		 3. Date of Earliest Transaction (MM/DD/YYYY)
10/12/2022
(Street)
MELVILLE, NY 11747
(City)        (State)        (Zip)
 4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
 6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  10/12/2022    P    725  A $3.3884  165103 (1) D   
Common Stock                 12136  I  IRA 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option  $3000.                   (2) 12/7/2022  Common Stock  1    1  D   
Stock Option  $3000.                   (2) 10/4/2023  Common Stock  1    1  D   
Stock Option  $3000.                   (2) 2/18/2024  Common Stock  3    3  D   
Stock Option  $3000                  3/12/2014  3/11/2024  Common Stock  1    1  D   
Stock Option  $3000                   (2) 10/23/2024  Common Stock  9    9  D   
Stock Option  $3000                   (2) 9/4/2025  Common Stock  6    6  D   
Stock Option  $3000                   (2) 6/10/2026  Common Stock  15    15  D   
Stock Option  $3000                   (2) 7/12/2027  Common Stock  20    20  D   
Stock Option  $3000                   (2) 10/29/2028  Common Stock  25    25  D   
Stock Option  $13.5                   (3) 3/18/2031  Common Stock  293479    293479  D   
Stock Option  $13.5                   (4) 11/4/2031  Common Stock  42059    42059  D   

Explanation of Responses:
(1)  Includes 104,045 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares on each of October 18, 2022, December 18, 2022 and February 18, 2023, 1,036 shares on each of November 18, 2022 and January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024.
(2)  The option is currently exercisable.
(3)  The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 and the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
(4)  The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Silva Francisco
40 MARCUS DRIVE
MELVILLE, NY 11747		 X
VP of Research and Development

Signatures
/s/ Francisco Silva 10/12/2022
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Feb 2023 to Mar 2023 Click Here for more BioRestorative Therapies Charts.
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more BioRestorative Therapies Charts.